Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Conditions
Interventions
Baricitinib
Placebo
+1 more
Locations
13
United States
Dermatology Research Associates
Los Angeles, California, United States
Forward Clinical Trials, Inc
Tampa, Florida, United States
Medical Dermatology Specialists
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Icahn School of Medicine
New York, New York, United States
Oregon Health and Science University
Portland, Oregon, United States
Start Date
February 1, 2016
Primary Completion Date
February 1, 2017
Completion Date
March 1, 2017
Last Updated
June 17, 2020
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions